Feb 9 The U.S. Food and Drug Administration on
Thursday approved Marathon Pharmaceuticals' Duchenne muscular
dystrophy (DMD) drug, Emflaza, to treat patients aged 5 years
DMD is a rare genetic disorder that causes progressive
muscle deterioration and weakness and had only one approved
treatment in the United States before Emflaza's approval.
The FDA in September approved Sarepta Therapeutics Inc's
DMD treatment even though an outside panel of experts
and the agency's own reviewers questioned the drug's efficacy.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by